Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies

Prognosis of patients with advanced sarcoma after progression from FDA approved therapies remains grim. In this study, clinical outcomes of 100 patients with advanced sarcoma who received treatment on novel targeted therapy trials were evaluated. Outcomes of interest included best response, clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Hess, Kenneth R., Khawaja, Muhammad Rizwan, Wagner, Michael J., Tang, Chad, Naing, Aung, Fu, Siqing, Janku, Filip, Piha-Paul, Sarina, Tsimberidou, Apostolia M., Herzog, Cynthia E., Ludwig, Joseph A., Patel, Shreyaskumar, Ravi, Vinod, Benjamin, Robert S., Meric-Bernstam, Funda, Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066200/
https://www.ncbi.nlm.nih.gov/pubmed/27748430
http://dx.doi.org/10.1038/srep35448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066200/
https://www.ncbi.nlm.nih.gov/pubmed/27748430
http://dx.doi.org/10.1038/srep35448

Ejemplares similares